MGNX vs AMPG Comparison

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.